An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs
Open Access
- 4 January 2016
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (6) , e1123368
Abstract
Insulin-like growth factor II mRNA-binding protein 3 (IMP-3), an oncofetal antigen identified using genome-wide cDNA microarray analyses, is overexpressed in several malignancies. IMP-3-derived cytotoxic T lymphocyte (CTL) epitopes have been used for peptide-based immunotherapies against various cancers. In addition to CTLs, induction of tumor-associated antigen (TAA)-specific helper T (Th) cells is crucial for establishment of effective antitumor immunity. In this study, we aimed to identify IMP-3-derived long peptides (IMP-3-LPs) carrying CTL and promiscuous Th-cell epitopes for use in cancer immunotherapy. IMP-3-derived Th-cell epitopes that bind to multiple HLA-class II molecules were predicted by in silico analysis, and their immunogenicity was determined by utilizing human T cells. We identified two highly immunogenic IMP-3-LPs presented by multiple HLA-class II molecules. One of the IMP-3-LPs encompassed two CTL epitopes that have been used for peptide-vaccine immunotherapy in ongoing clinical trials. IMP-3-LPs-specific Th cells responded to autologous dendritic cells (DCs) loaded with the recombinant IMP-3 proteins, suggesting that these s (LPs) can be naturally processed and presented. The IMP-3-LPs and specific Th cells augmented the expansion of IMP-3-specific CTLs, which was further enhanced by programmed cell death-1 (PD-1) blockade. In addition, IMP-3-LP encapsulated in liposomes was efficiently cross-presented in vitro, and this LP successfully cross-primed CTLs in HLA-A2 transgenic mice (Tgm) in vivo. Furthermore, one of the IMP-3-LPs induced IMP-3-specific Th cells from peripheral blood mononuclear cells (PBMCs) of head-and-neck malignant tumor (HNMT) patients. These findings suggest the potential usefulness of IMP-3-LPs in propagating both Th cells and CTLs and may have implications for IMP-3-LPs-based cancer immunotherapy.Keywords
This publication has 61 references indexed in Scilit:
- Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based VaccinationCancer Research, 2013
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigensJournal of Translational Medicine, 2012
- Peptide binding predictions for HLA DR, DP and DQ moleculesBMC Bioinformatics, 2010
- Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancerHead & Neck, 2010
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T LymphocytesCancer Research, 2010
- Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survivalBMC Cancer, 2010
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaJournal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus ApproachPLOS Computational Biology, 2008